Although there is a substantial body of pre-clinical evidence indicating that RANK signaling promotes the proliferation and metastatic progression of BC [4,18,19], there is still considerable debate as to whether the targeted inhibition of RANK signaling by denosumab treatment will confer clinical benefits in patients with early BC. Here, TNFRSF11A is linked to breast cancer.